雄激素受体在去势抵抗性前列腺癌进展中的作用及研究进展

摘要

Androgen receptor (AR)is an important factor in progression of prostate cancer.Androgen deprivation therapy (ADT)is the standard treatment for prostate cancer,and can effectively inhibit tumor growth at early stage. After two or three years,the prostate cancer can recur or grow into castration -resistant prostate cancer (CRPC).Now there are many papers about mechanisms of the occurrence and development of CRPC after therapy of ADT,which in-clude change of the steroid hormone metabolism,AR gene amplification or express,AR co -regulators,AR splicing variants,growth factors and /or cytokines,AR mutation,etc.But the specific mechanisms about CRPC are not fully un-derstood and agreed on.Now it is generally believed that androgen and androgen receptors play a key role in the devel-opment of CRPC.In this paper,the roles of AR on the mechanisms of CRPC are reviewed.%雄激素受体是前列腺癌发生发展的重要因素。雄激素去势疗法是目前治疗前列腺癌的标准疗法，在早期可以有效的抑制肿瘤生长。但2～3年内，肿瘤会复发或进展，形成去势抵抗性前列腺癌。目前关于雄激素去势疗法治疗后去势抵抗性前列腺癌发生发展机制研究的文献较多（其中包括类固醇激素代谢的变化、雄激素受体基因的扩增或过表达、雄激素受体辅助调节因子、雄激素受体剪接变异体、生长因子和／或细胞因子、雄激素受体突变等等机制），但还没有对具体机制完全了解并形成共识。目前普遍认为在去势抵抗性前列腺癌中，雄激素和雄激素受体在其发生发展中起到了关键的作用。本文就雄激素受体在前列腺癌进展为去势抵抗性前列腺癌的机制中的作用加以综述。